To include your compound in the COVID-19 Resource Center, submit it here.

Catabasis' edasalonexent misses primary in Phase II for DMD

In April, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported data from the Phase II portion of the U.S. Phase I/II MoveDMD trial in patients ages 4-7 with Duchenne muscular dystrophy (DMD) not on corticosteroids showing that edasalonexent (CAT-1004) missed the primary endpoint of improving muscle inflammation from baseline to week 12 vs. placebo. The endpoint was measured by MRI of

Read the full 583 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE